- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05928884
Echografie voor myofasciale pijn
Ontwikkeling en validatie van een niet-invasieve multimodale op echografie gebaseerde beeldvormende biomarker voor myofasciale pijn
The goal of this observational study is to develop and validate a biomarker for lumbar myofascial pain (MP) based on ultrasound obtained measurements of the lumbar muscles and fascia. The investigators will use advanced machine learning approaches and validation in a randomized controlled trial. The main questions it aims to answer are:
- Will the deep learning-based marker reliably identify subjects from the 4 different groups: healthy, MP without trigger points, MP with latent trigger points, and MP with active trigger points?
- Will the deep learning-based marker accurately classify/predict the severity of MP in subjects with cLBP?
Participants in the healthy group will be asked to do the following tasks:
- Consent/Enrollment
- Measure Height/Weight
- Complete Questionnaires on REDCap
- Participate in Ultrasound Imaging Experiment Sessions
Participants in the chronic low back pain group will be asked to do the following tasks:
- Consent/Enrollment
- Complete Questionnaires on REDCap
- Measure Height/Weight
- Undergo a Standardized Clinical Exam
- Participate in Ultrasound Imaging Experiment Sessions
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The investigators propose to use multimodal ultrasound imaging to develop and validate a practical and inexpensive biomarker for lumbar myofascial pain, which shows sensitivity to change in relation to treatment. Myofascial pain (MP) is a frequent contributing factor to chronic low back pain (cLBP). It is associated with a range of tissue abnormalities, such as taught muscle bands, trigger points (TPs), and thoracolumbar fascia motion dysfunction, along with poor tissue elasticity. As a result, a composite biomarker for MP related to components of the syndrome is more likely to be plausible biologically, robust, and useful clinically for diagnosis and treatment. The investigators propose to study: 1. The echogenicity of latent and active trigger points, 2. The dynamic spatial-temporal tissue deformation quantified by strain tensors (compression, extension, and shear) in the thoracolumbar fascia and multifidus muscle, 3. The viscoelastic properties of the fascia and muscles measured by ultrasound shear wave elastography. In the R61 Phase (year 1 to 3) the investigators will use deep learning to integrate these measurements into a predictive biomarker and use established validation methods to test its ability to predict MP.
The investigators will determine the sensitivity and specificity of the biomarker to classify the myofascial components of pain, as well as the response to treatment (a diagnostic and predictive marker).
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Kauffman Medical Building
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The investigators are including healthy normal and cLBP subjects from ages 20 to 70.
Beschrijving
Inclusion/Exclusion Criteria for Healthy Normals (n=40):
- No history of chronic low back pain, myofascial pain of the neck or shoulders, or fibromyalgia.
- Ages 20-70 to be age appropriate to the cLBP subjects. The investigators will recruit 10 subjects per age decile (10 subjects ages 30-39 yrs., etc.).
- Any clinically unstable systemic illness that is judged to interfere
- with the trial
- Non-ambulatory status
- Not able to complete the questionnaires.
Inclusion Criteria CLBP:
- Age range 20-70 so that the age distribution is likely to roughly match the healthy normals
- Predominantly axial cLBP meeting the NIH definition of cLBP (at least 3 months on a daily basis) with a MP component (determined by a standardized clinical exam)
- Average pain score of > 3/10, with low back pain being the primary pain site
- cLBP meeting Quebec Task Force Classification System categories I-III (from axial pain only to pain radiating beyond the knee without neurological signs).
Exclusion Criteria CLBP:
- Back surgery within the past year
- Active worker's compensation or litigation claims since these patients are more likely to have exaggerated pain behavior
- New pain treatments within 2 weeks of enrollment
- Any clinically unstable systemic illness that is judged to interfere with the trial
- Non-ambulatory status
- Not able to complete the questionnaires.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Healthy Normals
Participants with no chronic pain over a three-year timeframe. |
See above, this is only a phenotyping study but NIH required us to register it as a trial. |
|
MP without TPs
Participants with chronic low back pain who are classified as having myofascial pain and no trigger points. |
See above, this is only a phenotyping study but NIH required us to register it as a trial. |
|
MP with latent TPs
Participants with chronic low back pain who are classified as having myofascial pain and latent trigger points. |
See above, this is only a phenotyping study but NIH required us to register it as a trial. |
|
MP with active TPs
Participants with chronic low back pain who are classified as having myofascial pain and active trigger points. |
See above, this is only a phenotyping study but NIH required us to register it as a trial. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnosis of one of 3 MP-related categories
Tijdsspanne: Study Visit 1 (week 1)
|
Participants to be diagnosed as normal, MP with trigger points, or MP with tender points only, as determined by standardized clinical examinations. |
Study Visit 1 (week 1)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Presence of Substantial MP
Tijdsspanne: Study Visit 1 (week 1) - Study Visit 2 (week 2)
|
The presence of substantial MP (e.g., # active TPs and pressure pain threshold below 6.5 N/cm2) as determined by the standardized clinical examinations. |
Study Visit 1 (week 1) - Study Visit 2 (week 2)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Kang Kim, PhD, University of Pittsburgh
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- STUDY22090014
- 1R61AT012282-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Depends on the specific request from an outside party
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .